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Abstract
Background: Histone deacetylase inhibitors (HDACis) re-express silenced tumor suppressor genes and are currently
undergoing clinical trials. Although HDACis have been known to induce gene expression, an equal number of genes are
downregulated upon HDAC inhibition. The mechanism behind this downregulation remains unclear. Here we provide
evidence that several DNA repair genes are downregulated by HDAC inhibition and provide a mechanism involving the
E2F1 transcription factor in the process.
Methodology/Principal Findings: Applying Analysis of Functional Annotation (AFA) on microarray data of prostate cancer
cells treated with HDACis, we found a number of genes of the DNA damage response and repair pathways are
downregulated by HDACis. AFA revealed enrichment of homologous recombination (HR) DNA repair genes of the BRCA1
pathway, as well as genes regulated by the E2F1 transcription factor. Prostate cancer cells demonstrated a decreased DNA
repair capacity and an increased sensitization to chemical- and radio-DNA damaging agents upon HDAC inhibition.
Recruitment of key HR repair proteins to the site of DNA damage, as well as HR repair capacity was compromised upon
HDACi treatment. Based on our AFA data, we hypothesized that the E2F transcription factors may play a role in the
downregulation of key repair genes upon HDAC inhibition in prostate cancer cells. ChIP analysis and luciferase assays reveal
that the downregulation of key repair genes is mediated through decreased recruitment of the E2F1 transcription factor and
not through active repression by repressive E2Fs.
Conclusions/Significance: Our study indicates that several genes in the DNA repair pathway are affected upon HDAC
inhibition. Downregulation of the repair genes is on account of a decrease in amount and promoter recruitment of the E2F1
transcription factor. Since HDAC inhibition affects several pathways that could potentially have an impact on DNA repair,
compromised DNA repair upon HDAC inhibition could also be attributed to several other pathways besides the ones
investigated in this study. However, our study does provide insights into the mechanism that governs downregulation of HR
DNA repair genes upon HDAC inhibition, which can lead to rationale usage of HDACis in the clinics.
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Introduction
Epigenetic regulation of gene expression is thought to be
brought about by both chromatin modulators that modify N-
terminal tails of histones and DNA methylating enzymes that
methylate CpG clusters in the promoter regions of eukaryotic
genomes [1,2,3]. Cancer cells modulate the epigenetic machinery
to silence tumor and metastatic suppressors to gain selective
growth and invasive properties [4,5,6]. The HDAC class I and
class II enzymes form complexes with co-repressors such as NuRD
and the SMRT/NCoR complexes [7]. Cancer cells, including
prostate cancer (PCa), recruit different HDACs associated with
these large multi-protein co-repressor complexes to silence tumor
suppressor genes and this serves as one rationale for the use of
HDACis to treat cancer [8,9].
The activity of both class I and class II HDACs is inhibited by
short chain fatty acids (Phenylbutyrate, Valproic acid (VPA)) and
hydroxamic acids (Vorinostat, Trichostatin A), while benzamides
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(MS-275) appear to be specific to Class I HDACs [8]. Conversely,
class III HDACs, the sirtuins, are not inhibited by any of these
agents [10]. Recently, Vorinostat has been approved by the FDA
for the treatment of cutaneous T cell lymphoma. We and others
have shown that treatment of PCa with HDACis or DNA
methyltransferase inhibitors relieves the repression, causing
reexpression of silenced tumor suppressors leading to cell cycle
arrest, senescence and apoptosis [11,12,13]. The combination of
HDACis with other agents has been shown to be effective for a
wide variety of cancers. Although HDACis have been known to
upregulate a number of genes, paradoxically an equal number of
genes are repressed upon HDAC inhibition [14,15,16]. Repres-
sion of genes upon HDAC inhibition can be the result of indirect
actions of repressors that are activated and cause repression in an
HDAC passive fashion, or repression could be brought about by
active recruitment of HDACs to promoters of selected genes [17].
Pathways that are downregulated upon HDAC inhibition create
settings for treatment modalities that are ineffective in their
presence. Recent reports suggest that HDACis such as phenyl
butyrate, VPA, MS-275 and SAHA can potentiate radiation
sensitivity of cancer cells [18,19,20,21]. Transcriptional downreg-
ulation of certain genes involved in the homologous recombination
(HR) and non-homologous end joining (NHEJ) DNA repair
pathways have been implicated [18,19,20,22].
Double strand breaks (DSBs) can be induced by endogenous
agents such as reactive oxygen species and replication stress by
stalled replication forks, or can be induced by exogenous agents
like ionizing radiation [23]. It is increasingly evident that DNA
damage is sensed by protein complexes, termed DNA damage
sensors, which in turn induce a signal transduction cascade that
recruit mediator and effector proteins to the damaged sites,
leading to the repair of DNA [24]. Depending upon the extent of
damage, further signal transduction alerts the cell to either delay
the cell cycle through checkpoint activation for repair processes to
complete, or undergo apoptosis [24]. Each type of DNA damage is
sensed and repaired by distinct DNA repair pathways. The MRN
complex, consisting of Mre11-Rad50-NBS1 mediator complex,
senses DSBs and recruits ATM, a PI3K-like kinase, to the site of
DSBs [25]. ATM is activated after recruitment to DSBs and
phosphorylates downstream substrates, initiating the signal
transduction process [26].
ATM and related kinases, ATR and DNAPK, phosphorylate a
histone variant c-H2AX at ser-139 which loads to sites of DSBs
and covers megabases flanking the DSBs; this constitutes the
irradiation induced foci. Phosphorylated c-H2AX recruits several
mediator proteins [27]. Among these mediators are the BRCA1
associated surveillance complex and 53BP1. The signal transduc-
tion cascade is further amplified by transducer checkpoint kinases,
CHK1 and CHK2, which are activated upon phosphorylation by
ATM and ATR. ATM and ATR together with CHK1/CHK2
kinases phosphorylate a number of effector substrates that include
BRCA1, Rad51, p53, and Mdm2 [28]. Phosphorylation of p53
leads to its stabilization, causing a cell cycle arrest through
induction of p21, or in the event of greater DNA damage,
apoptosis. Stalled replication forks that arise due to DNA damage
and replication stress, are sensed by PCNA related Rad9-Rad1-
Hus1 or the 911 complex, whose recruitment to the stalled site is
mediated by replication protein A and ATR. The final effector
proteins that repair the damaged DNA are activated and recruited
by the above mentioned kinases and mediator proteins to the site
of damage and repair ensues.
Genes of the DNA repair pathways are tightly regulated both at
the transcriptional and post transcriptional level. At the transcrip-
tional level, the E2F transcription factors have been known to play
a role in regulating repair proteins. There are nine known E2F
transcription factors that can be divided into transcriptional
activators (E2F1, E2F2, E2F3a) and repressors (E2F4-8); E2F3b
has been hypothesized to function as a repressor [29]. E2F1 and
E2F4 have been implicated in the regulation of CHK1, BRCA1
and RAD51 genes [30,31,32].
Recently, we reported a novel ‘‘multiple-loop, double-cube’’
cDNA microarray design, to analyze HDAC inhibitor induced
changes in gene expression across sensitive and resistant PCa cell
lines [16]. Applying Analysis of Functional Annotation (AFA) on
the data set from the above microarray experiment we found that
several genes of the HR repair and DNA damage response
pathway are downregulated upon HDAC inhibition. In this
report, we demonstrate transcriptional downregulation of several
DNA damage response genes in PCa cells upon HDAC inhibition,
provide functional evidence of the involvement of HR repair
pathway in compromised DNA repair, and provide a role of the
E2F1 transcription factor in the downregulation of DNA damage
response genes.
Results
AFA reveals HDACis downmodulate several genes of the
DNA damage and response pathway in PCa
AFA was performed on our recently published microarray data
set of two PCa cell lines (PC3 and DU-145) treated with vorinostat
(previously known as SAHA) and VPA [16]. The analysis revealed
downregulation of several genes involved with DNA damage
response and repair (Table 1). Protein-protein interaction analysis
on the microarray data revealed several genes related to the E2F1
and BRCA1 pathways were downregulated with both HDACis
more than 1.3 fold in both PCa cells lines (Fig. 1a). Many of these
downregulated genes are involved in the HR DNA repair
pathway. Surprisingly, the NHEJ pathway related genes, specif-
ically DNAPK and Ku, were not affected in our arrays. Earlier
reports have shown that RAD51 is downregulated upon HDAC
inhibitor treatment in a variety of cell lines [18,19,20]. Our
microarray data revealed that besides Rad51 and related genes, a
wide variety of genes involved in the DNA damage response and
repair pathway such as Brca1, Chk1, Topo IIa, Hus1, and Bubr1,
were downregulated upon HDAC inhibitor treatment (Fig. 1b).
In order to understand the consequence of downmodulation
and gain more insights into the mechanism behind the down-
modulation, we performed further analysis using two PCa cell lines
(DU-145 and LNCaP) using the HDAC inhibitor VPA. To
validate our microarray data, we performed a Q-PCR analysis on
a subset of repair genes. Our data revealed that all the genes tested
were downregulated in both of the cell lines, except Hus1 which
was downregulated only in LNCaP cells (Fig. 1c). BRCA1, Rad51
and Chk1 are known to be regulated by the E2F transcription
factor [30,31]. Since the AFA revealed enrichment for down-
modulation of E2F1 target genes, including E2F1 itself, we
investigated the transcript level of both the activator (E2F1) and
repressor E2F (E2F4 and 6) transcription factors. Our results show
that E2F1 was significantly downregulated in both the cell lines
treated with VPA, while the repressor E2Fs were not affected in
either of the cells lines upon VPA treatment (Fig. 1c).
Downmodulation of DNA repair genes by HDAC
inhibition leads to an increased sensitivity of PCa cells to
DNA damaging agents.
Previous reports from our group and others have demonstrated
that HDACis like VPA can decrease proliferation of prostate
cancer cells[11,16]. HDACis have also been known to act as
HDAC Inhibition and E2F1
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radiosensitizers [18,19,20]. We hypothesized that downmodula-
tion of DNA repair genes upon HDAC inhibition would lead to an
increased sensitivity to various DNA damaging agents. DU-145
cells were subjected to clonogenic survival assays after treatment
with a combination of HDACis and different agents that induce
DSBs such as radiation, cisplatin and hydroxyurea. A radiosen-
sitivity clonogenic assay was performed with increasing dosages of
VPA in the presence of an increasing dosage of radiation. As
expected, VPA did radiosensitize DU-145 cells, and there was an
increase in sensitivity with increasing dosages (Fig. 2a). Recently, it
has been demonstrated that a defect in homologous recombination
can lead to changes in drug sensitivity profile, rendering the
BRCA1 deficient breast cancers sensitive to mitomycin C,
cisplatin, etoposide and other drugs that produce double-stranded
lesions [33]. We argued that this may be true for HDACi treated
PCa cells, where there is a decrease in BRCA1 pathway related
gene expression. Clonogenic assays performed after treatment of
DU-145 cells with VPA alone or in combination with cisplatin and
hydroxyurea, revealed that in comparison to a single agent, the
combination of VPA with either hydroxyurea or cisplatin greatly
decreased clonogenic survival (Fig. 2b and c).
HDAC inhibition by VPA leads to a decrease in DNA
repair proteins of the HR and DNA Damage Response
pathway
Sensitivity to various DNA damaging agents upon HDAC
inhibition could be the result of compromised or subnormal DNA
repair ability in treated cells. This can be brought about by the
downregulation of DNA repair genes upon HDAC inhibition.
Radiosensitization of HDACis has been linked to a decrease in
Rad51 gene expression in PCa [20]. To first test whether VPA
causes a decrease in double strand break DNA repair capacity of
PCa cells we performed a neutral comet assay to assess for DNA
repair ability of prostate cancer cells upon HDAC inhibition
[34,35]. Under the experimental conditions used, we did not find
any statistical difference in the tail moment of VPA treated and
untreated control cells without radiation. However, in the absence
of VPA treatment cells exposed to 4 Gy of irradiation were able to
repair most of their damaged DNA within 4 hours. However after
VPA treatment both prostate cell lines showed significantly higher
tail moments 4 hours after exposure to 4 Gy of irradiation
suggesting reduced DNA repair capacity (Fig. 3a). To determine
whether the DSB repair is compromised upon HDAC inhibition,
Table 1. Analysis of Functional Annotation results for gene ontology.
VPA SAHA
GO identifier Ontology GO Term Time PC3 DU145 PC3 DU145
GO:0000077 BP DNA damage checkpoint 48 hs .0.10000 0.06593 .0.10000 .0.10000
96 hs .0.10000 .0.10000 0.04165 .0.10000
GO:0003684 MF damaged DNA binding 48 hs 0.04926 0.01893 .0.10000 0.00537
96 hs 0.00329 0.01312 .0.10000 0.03314
GO:0006974 BP response to DNA damage stimulus 48 hs ,0.00001 ,0.00001 0.03633 ,0.00001
96 hs ,0.00001 ,0.00001 ,0.00001 ,0.00001
GO:0042770 BP DNA damage response, signal
transduction
48 hs 0.07854 0.01562 0.04007 .0.10000
96 hs .0.10000 0.04847 0.03714 .0.10000
GO:0006281 BP DNA repair 48 hs ,0.00001 ,0.00001 .0.10000 ,0.00001
96 hs ,0.00001 ,0.00001 0.00007 ,0.00001
GO:0006302 BP double-strand break repair 48 hs 0.08622 0.00008 .0.10000 0.00437
96 hs 0.02245 0.00011 .0.10000 0.01144
GO:0006284 BP base-excision repair 48 hs 0.00182 0.00510 0.02607 0.00442
96 hs 0.00031 0.00204 0.08656 0.00286
GO:0006298 BP mismatch repair 48 hs .0.10000 .0.10000 .0.10000 .0.10000
96 hs 0.05092 .0.10000 .0.10000 .0.10000
GO:0006289 BP nucleotide-excision repair 48 hs .0.10000 .0.10000 .0.10000 .0.10000
96 hs 0.07408 .0.10000 .0.10000 .0.10000
GO:0000724 BP double-strand break repair via
homologous recombination
48 hs .0.10000 0.01723 .0.10000 0.03906
96 hs .0.10000 0.01551 .0.10000 0.09229
GO:0000725 BP recombinational repair 48 hs .0.10000 0.01723 .0.10000 0.03906
96 hs .0.10000 0.01551 .0.10000 0.09229
GO:0045739 BP positive regulation of DNA repair 48 hs .0.10000 .0.10000 .0.10000 0.07948
96 hs .0.10000 .0.10000 .0.10000 0.07583
GO:0006310 BP DNA recombination 48 hs 0.01415 0.00001 .0.10000 0.00107
96 hs 0.00036 ,0.00001 .0.10000 0.00009
The enrichment driven by down-regulation of gene expression showed an overall involvement of processes related to the response of DNA damage. The reports the
P-values obtained from the Wilcoxon rank-sum test after correction for multiple testing by the Benjamini-Hochberg method.
doi:10.1371/journal.pone.0011208.t001
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we employed H2AX foci clearance as an indicator of efficient DSB
repair. DU-145 and LNCaP cells were treated with VPA and
irradiated with 2 Gy, 4 Gy, and 6 Gys of radiation. Cells were
fixed after 4 h of repair and probed with Ser139 phosphorylated
H2AX antibodies. As expected, an increase in H2AX foci was
found in PCa cells treated with VPA, indicating a decrease in
DNA repair capacity (Fig. 3b). Compromised DNA repair can be
the result of a decrease in the total amounts of repair protein and/
or a decrease in localization or recruitment of repair proteins to
the damaged site. To test these possibilities, we first investigated
the levels of repair proteins that were shown to be downmodulated
in our microarray dataset after VPA treatment. Many of these
genes, such as Rad51, Brca1 and Chk1, are induced upon DNA
damage [24]. To investigate whether these proteins remain
downregulated upon HDAC inhibition even upon DNA damage,
we performed our analysis in the absence and presence of
radiation. An increase in total H3 acetylation in DU-145 and
LNCaP cells demonstrated that VPA does cause an effective global
Figure 1. Analysis of Functional Annotation (AFA) in HDACi treated PCa cells. a) DU145 and PC3 cells were treated with two different
HDACis (vorinostat (SAHA, 1 mM), and VPA (Valproic acid, 1 mM) for incubation periods (2days and 4days). AFA reveals down-regulation of genes
involved with DNA damage and response (see Table 1). AFA results for protein-protein interaction indicate BRCA1 and E2F interacting networks are
affected by HDAC inhibition. Color code represents as 10-n the p-values obtained from the Wilcoxon rank-sum test. b) DNA repair genes
downregulated $1.3 fold in both PC3 and DU-145 cells upon treatment with both VPA and vorinostat. c) Validation of the AFA was done by a Q-PCR
analysis on a subset of genes downregulated upon 1.5 mM VPA treatment. Results are depicted as fold change over untreated control cells.
doi:10.1371/journal.pone.0011208.g001
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HDAC inhibition at the dosage used for the experiments (Fig. 4a
and data not shown). Increasing the concentration of VPA causes
a decrease in BRCA1 and Rad51 in both DU-145 and LNCaP
cells, while other repair proteins such as DNAPK and NBS1
remain unaffected (Fig. 4b and c). BRCA1 protein levels are not
steady in the cell, and peaks at different time points depending on
the phase of the cell cycle. In order to understand when BRCA1 is
downregulated in VPA treated cells, lysates were collected at each
time point after treatment. BRCA1 was found to decrease as early
as 18 h after treatment (Fig. 4c), indicating a rapid response upon
HDAC inhibition. Irradiation of PCa cells, post treatment with
VPA, demonstrated certain DNA damage response and repair
proteins such as ATR and NBS1 remained unaffected, while
DNAPK was induced upon VPA treatment in the presence of
radiation (Fig. 5a). RAD51, BRCA1 and CHK1 were found to
remain downregulated even upon irradiation in VPA treated cells.
BRCA1 is a nuclear protein, which distributes to the cytoplasm
under certain conditions. To ascertain that treatment with VPA
results in the downregulation of BRCA1 in the nuclear
compartment, DU-145 cells were treated with VPA and irradiated
48 h posttreatment with 4 Gy of radiation. Nuclear extracts
prepared from these cells were immunoprobed for BRCA1. As
shown in Fig. 5b, VPA treated cells have a downregulation of
BRCA1 protein even after irradiation.
Our results had indicated a marked reduction in TOPO IIa
transcript levels upon treatment with VPA. TOPO IIa resolves
catenated DNA by inducing a transient DSB and subsequent
religation [36]. TOPO IIa has been implicated in a variety of
cellular processes including DNA replication, transcription and
chromosome segregation [37]. We expected downregulation of the
TOPO IIa protein after HDAC inhibition. To our surprise, we
found TOPO IIa protein is upregulated upon VPA treatment in
both prostate cell lines (Fig. 5c and data not shown). To investigate
whether this leads to an increase in activity of the TOPO IIa
protein, we used nuclear extract from VPA treated DU-145 cells
to measure decatenation activity of TOPO IIa. As seen in Fig. 5c,
VPA treated cells decatenated kinetoplast DNA more efficiently
than untreated control cells. This suggests that although TOPO
IIa is downregulated at the transcript level upon HDAC
inhibition, there exists a post translational regulation whereby
the protein is stabilized upon HDAC inhibition.
Recruitment of key HR DNA repair proteins is affected
upon HDAC inhibition leading to a decrease in HR DNA
repair
Spatial and temporal recruitment of mediator and DNA repair
proteins to the irradiation induced foci is necessary for efficient
DNA repair to occur [24]. We investigated whether a decrease in
DNA damage response and repair proteins upon HDAC
inhibition also led to a decrease in recruitment of DNA repair
proteins to the damaged site. VPA treated DU-145 and LNCaP
Figure 2. Sensitivity of DU-145 cells to DNA damaging agents upon VPA treatment. a) Clonogenic assay performed in DU-145 after
treatment with different doses of VPA for 48 h before irradiation with different doses of radiation. Top panel shows representative clonogenic plates
with 0Gy and 4 Gy radiation graph below depicts surviving fraction after VPA treatments and irradiation. Error bar represents standard deviation of
three independent experiments. b) Clonogenic assay performed on DU-145 cells treated with 1.5 mM VPA and cisplatin (100 nM and 250 nM) for
48 h. Error bar represents standard deviation. c) Clonogenic assay performed on DU-145 cells treated with 1.5 mM VPA and hydroxyurea (0.5 mM and
1 mM) for 48 h. Error bar represents standard deviation.
doi:10.1371/journal.pone.0011208.g002
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cells were irradiated with 4 Gy of radiation and subsequently fixed
after four hours of repair.
Immunofluorescence was carried out for BRCA1 and RAD51
along with phosphorylated H2AX proteins. There was a marked
reduction in the staining for BRCA1 and RAD51 foci upon VPA
treatment; control cells on the other hand showed discrete BRCA1
and RAD51 foci that colocalized with phosphorylated H2AX
(Fig. 6a and b). The staining and localization of NBS1, however,
Figure 3. VPA treated prostate cancer cells show decreased repair capacity and c-H2AX clearance. a) Neutral comet assay performed on
prostate cancer cells treated with 1.5 mM VPA for 48 h and irradiated with 6 Gy c- radiation followed by a 4 h repair interval. Unirradiated cells (0Gy)
with and without VPA treatment did not show any significant difference in comet tail moments. The graph depicts average tail moment of 50 cells
error bar indicates SD value of three experiments. Comparisons have been performed using the student’s t-test. b) Immunofluorescence showing
H2AX Ser139 staining in DU-145 cells treated with 1.5 mM VPA for 48 h and irradiated with 4Gy radiation followed by 4 h repair time. The graph
shows quantitation of H2AX foci in control (blue column) and treated (red column) DU-145 and LNCaP cells. Error bar represents standard deviation
of three independent experiments.
doi:10.1371/journal.pone.0011208.g003
Figure 4. Repair protein in prostate cancer cells treated with VPA. a) Western blot showing acetylation of histone H3 protein in DU-145 cells
after treatment with different doses of VPA for 48 h. b) DNAPK and NBS1 protein levels in VPA treated DU-145 cells for 48 h. c) Western blot showing
RAD51 and BRCA1 protein levels in LNCaP and DU-145 cells treated with varying dosage of VPA for 48 h. Blot on the right shows DU-145 cells treated
with 1.5 mM VPA for varying timepoints probed for BRCA1 protein.
doi:10.1371/journal.pone.0011208.g004
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remained unchanged after VPA treatment (Fig. 6a). We quantified
the number of BRCA1 and RAD51 foci by counting them in cells
having more than twenty H2AX foci. As shown in figure 6c, we
found that there was a significant reduction in the number of
repair foci for both of the repair proteins upon VPA treatment.
Both LNCaP and DU-145 cells showed punctate cytoplasmic
staining for both RAD51 and BRCA1. These results indicate that
besides downregulation, there is an impaired recruitment of the
repair proteins to the damaged site upon HDAC inhibition.
Whether this leads to a decrease in HR repair was the next
question we investigated. For this, we employed a plasmid based
approach to score for HR efficiency in LNCaP cells. We generated
an EGFP recombination reporter construct by cloning a
promoterless EGFP upstream of the pEGFPN1 vector. A Bcl I
site was engineered in this gene to induce DSBs. The EGFP gene
ahead of the CMV promoter was mutated, with the consequence
that the functionality of EGFP would only be restored when there
is efficient HR repair. As shown in the figure 6d, there was a
significant reduction in the number of HR proficient LNCaP cells
upon VPA treatment. These results clearly indicate an involve-
ment of the HR pathway in PCa cells upon HDAC inhibition.
E2F1 is involved in downregulation of key repair proteins
upon HDAC inhibition
Since our data demonstrated transcriptional downregulation of
repair genes upon HDAC inhibition, we investigated the histone
H3 acetylation status of promoters of a subset of downregulated
genes using ChIP assays. Intriguingly, our results revealed a
decrease in H3 acetylation status of the proximal promoter regions
of all the genes investigated (Fig. 7a). A decrease in acetylation of
promoter regions is also accompanied by an increase in binding of
transcriptional repressor proteins to the promoters [7]. To
investigate transcription factors that can bring about transcription
repression of DNA repair genes upon HDAC inhibition, we
focused our attention on the E2F transcription factors. Brca1 and
Rad51 have two E2F binding site in the proximal promoter region
[31]. Both Brca1 and Rad51 are repressed under hypoxic
conditions by recruitment of E2F4/p130 transcription repressors.
Under hypoxic conditions, E2F1 and E2F4 simultaneously bind
the Brca1 promoter at two adjacent E2F sites to bring about
transcriptional repression of BRCA1 gene expression [30,31].
Similarly, Chk1 and BubR1 have transcription binding sites for
E2F transcription factors and are induced by E2F1[32,38].
Since E2F1 transcript was downregulated by HDACis, we
hypothesized that HDAC inhibition may increase the binding of
repressive E2Fs to downregulated repair gene promoters, and thereby
result in active repression of DNA repair genes. We first investigated
protein levels of both the activator and repressive E2Fs after
treatment with VPA in both LNCaP and DU-145 cells. In
accordance with the transcript levels, the E2F1 protein level was
downregulated upon VPA treatment, while the repressive E2Fs
(E2F4 and 6) did not change. E2F1 remained downregulated even
Figure 5. Repair protein levels in VPA treated PCa cells followed by irradiation. a) PCA cell lines treated with 1.5 mM VPA for 48 h,
irradiated with different doses of radiation, probed for various repair proteins by western blotting. Unirradiated (0Gy cells) were also included. b) Total
and nuclear extract of VPA (1.5 mM for 48 h) treated DU-145 cells with and without irradiation probed for BRCA1 protein. Unirradiated (0Gy cells)
were also included. c) Top panel shows TOPO IIa protein level in nuclear extract from DU-145 cells upon VPA treatment. Bottom panel is an agarose
gel showing TOPO IIa activity in the same extracts, lane 4 is a negative control.
doi:10.1371/journal.pone.0011208.g005
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after induction of DNA damage by irradiation (Fig. 7b). Thus there is
a differential response of the activator and repressive E2Fs to HDAC
inhibition. There are reports that suggest an increase in E2F1
transcriptional activity during neuronal apoptosis upon HDAC
inhibition [39]. This could be tissue-dependent, as vorinostat
mediated HDAC inhibition results in downregulation of E2F related
genes in multiple myeloma [40]. Further, binding of E2F1 to the
ARHI promoter was shown to be reduced by the HDAC inhibitor
trichostatin A [41]. Although we found E2F1 protein levels
downregulated upon HDAC inhibition, there was a possibility that
the activity of the remaining pool of E2F1 was increased after HDAC
inhibition. To investigate this, we cloned proximal regions of Brca1,
Rad51, and Chk1, which encompasses the E2F binding sites, into the
pGL3 basic luciferase reporter vector. VPA treated DU-145 and
Figure 6. Recruitment of HR repair proteins to the damaged site and HR repair in VPA treated PCa cells. a) Immunofluorescence
analysis of DU-145 cells treated with 1.5 mM VPA for 48 h and irradiated with 4Gy of radiation probed for BRCA1 (red) and NBS1 (green). Nuclei were
counterstained with DAPI. Cytoplasmic BRCA1 (arrow) seen in VPA treated cells suggest impaired recruitment of BRCA1 in VPA treated cells. b)
Immunofluorescence analysis of LNCaP cells treated with 1.5 mM VPA for 48 h and irradiated with 4Gy of radiation probed for H2AX Ser139 (red) and
RAD51 (green). Nuclei were counterstained with DAPI. Cells having .25 H2AX Ser139foci were analyzed. Cytoplasmic RAD51 (arrow) seen in VPA
treated cells suggest impaired recruitment of BRCA1 in VPA treated cells. c) Quantification of the number of BRCA1 and RAD51 foci colocalizing with
H2AX Ser139 foci in DU-145 and LNCaP cells after treatment with 1.5 mM VPA and irradiation with 4Gy of radiation. A total of 100 cells having .25
H2AX Ser139foci were counted. Error bars indicate standard deviation from mean. d) FACS analysis depicting a HR repair assay using a plasmid
reporter construct in LNCaP cells after treatment with varying concentration of VPA.
doi:10.1371/journal.pone.0011208.g006
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LNCaP cells were transfected with the promoter reporter constructs
along with control Renilla luciferase vector. Lysates were subjected to
a dual- luciferase assay. Our data revealed a significant downregu-
lation of all the gene promoters upon VPA treatment, with the
BRCA1 promoter being the most affected, as compared to control
cells (Fig. 7c). Whether this involves decreased binding of E2F1 or
increased binding of repressive E2F4 or E2F6 to the downregulated
gene promoters was the next question we addressed. Primers for
ChIP assays were designed to flank the E2F sites in proximal
promoters of Brca1, Rad51, Chk1 and Bubr1 genes. Chromatin from
VPA treated and untreated control cells was immunoprecipitated
using antibodies against E2F1, E2F4 and E2F6. PCR amplification of
precipitated chromatin DNA revealed promoter occupancy of these
transcription factors. Corroborating a previous report, we did find
simultaneous occupancy of E2F1 and E2F4 to Brca1 and Rad51 gene
promoters and found a similar pattern for the Bubr1 promoter.
Under our experimental conditions, we did not find any E2F6
binding to any of the promoters investigated. While E2F1 bound
strongly to promoter regions in untreated controls, there was a
significant reduction of E2F1 recruitment upon HDAC inhibition
(Fig. 7d). Contrary to our hypothesis, we found that the
downregulation of the repair genes is not as a result of active
repression by repressive E2Fs, but an overall decrease in the
recruitment of activator E2F1 to the promoters.
Discussion
During the evolution of PCa, certain DNA repair pathways are
inactivated, as a result of which, PCa acquires genomic instability.
This accounts for a greater level of endogenous DNA damage in PCa
cells than normal cells [42,43]. For continued cell survival, other
DNA damage response and repair pathways are induced and
maintained. Therapeutics aimed at disabling remaining DNA repair
pathways in PCa together with appropriate DNA damage inducers,
may provide an effective therapy. Experimental evidence suggests
HDACi can act as radiosensitizers for a wide variety of cancers
including PCa [44]. Downregulation of repair genes has been
implicated in this process. Specifically, Ku70, Ku86, and the
DNAPK catalytic subunit were shown to be downregulated in
melanoma cells, while Rad51 and DNAPK were downregulated in
PCa cells upon HDAC inhibition [20,45]. However, functional
evaluation of specific DNA repair pathways upon HDAC inhibition
has not been demonstrated. Moreover, the mechanism behind
downregulation of these repair genes has not been elucidated.
We applied AFA on a microarray data set from PCa cells
treated with HDACis. Our protein-protein interaction analysis
revealed downregulation of several DNA repair genes that were
related to BRCA1. Many of these genes are involved in the HR
DNA repair pathway. The HR pathway is mediated by BRCA1
and executed by the RecA homolog Rad51 DNA recombinase, a
key protein in the HR pathway [23]. Both these proteins were
downregulated on HDAC inhibitor treatment. Genes of the NHEJ
DNA repair pathway remained unaffected. We quantified the
expression of a subset of downregulated genes both at the
transcript and protein level. Downregulation after HDAC
inhibitor treatment was also noted at both levels, even in the
presence of radiation as a DNA damaging agent. Intriguingly,
TOPO IIa, which was downregulated at the transcript level, was
Figure 7. Downregulation of E2F1 mediates downregulation of DNA damage and response genes. a) ChIP analysis of VPA (1.5 mM for
48 h) treated DU-145 cells for acetylated histone H3 status in the promoters of repair genes. The bar diagram is a densitometry reading of the agarose
gel shown normalized to inputs. b) Activator and repressor E2F protein levels in VPA (1.5 mM for 48 h) treated cells LNCaP and DU-145 cells.E2F levels
remained downregulated upon VPA treatment even after irradiation with 4Gy radiation as shown in DU-145 cells, unirradiated (0Gy) cells served as a
radiation control. c) Luciferase reporter assays in DU-145 and LNCaP cells, treated with varying concentrations of VPA, using proximal promoter
regions, encompassing E2F binding regions of downregulated repair genes. d) ChIP analysis for E2F occupancy in the promoter regions of
downregulated genes. ChIP was performed using antibodies against E2Fs (1, 4, and 6) in VPA (1.5 mM for 48 h) treated and control DU-145 cells. The
bar diagram represents densitometric readings normalized to respective inputs.
doi:10.1371/journal.pone.0011208.g007
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stabilized at the protein level. An increase in the protein level
correlated with an increase in decatenation acitivity. While TOPO
IIa is essential for cell survival and viability, increased activity
leads to an increase in DSBs and fragmentation of DNA. This,
coupled with a decrease in repair proteins upon HDAC inhibition,
can potentially lead to an increase in unrepaired DNA breaks
leading to a decrease in cell survival.
As predicted, treatment of PCa cells with a combination of
HDAC inhibitor and DNA damaging agents like radiation,
cisplatin and hydroxyurea lead to decreased survival. We
attempted to understand the mechanism behind this increased
sensitivity to DNA damaging agents upon HDAC inhibition. We
found that besides downregulation there is an impaired recruit-
ment of key HR repair proteins (BRCA1 and RAD51) to the DNA
DSBs. Punctuate cytoplasmic staining was observed for these
repair proteins upon VPA treatment. Cytoplasmic retention of
both BRCA1 and RAD51 has also been reported in fibroblasts
upon FGF stimulated induction of AKT1, which results in a
decrease in HR DNA repair. We do not know whether
cytoplasmic BRCA1 and RAD51 observed upon VPA treatments
is as a result of active nuclear export of BRCA1 and RAD51 upon
HDAC inhibition, or as a result of cytoplasmic retention of these
proteins en-route to the nucleus. We assessed the functional
consequence of downregulation and impaired recruitment of these
HR repair proteins by a HR repair assay. We found a marked
reduction in HR DNA repair capacity of PCa cells upon HDAC
inhibition.
Recent studies have highlighted the importance of post
translational histone modifications in transcriptional regulation
of genes. Our study indicated a decrease in activator H3
acetylation marks in the promoter regions of the downregulated
genes. How certain gene promoters maintain low histone
acetylation status in the presence of HDACis is intriguing. One
simple explanation could be that certain HDACs that are present
in corepressors complexes are less susceptible to inhibition by
HDACis, and are actively involved in repression of certain gene
promoters. This has been noted in downregulation of DNMT1 by
the HDAC inhibitor apicidin [17]. Recent studies indicate that the
repressive E2F transcription factors can mediate or maintain the
repressive histone modification, while activation histone marks are
important in recruitment of activator E2Fs (E2F1-3) [46]. In order
to understand the mechanism behind downregulation, we focused
our attention on the E2F transcription factors. AFA indicated that
E2F1 regulated genes were affected upon HDAC inhibition.
Several DNA repair and response genes that were downregulated
in our data set, such as Brca1, Rad51, Chk1, and Bubr1, are E2F
targets. We observed that downregulation of DNA repair genes
was not as a result of active repression by recruitment of repressive
E2Fs to downregulated gene promoters, but was as a result of
decreased recruitment of activator E2F1. Currently we are
investigating whether this downregulation is through the active
recruitment of HDACs or a decreased recruitment of HATs to the
downregulated promoters.
In summary, our study indicates that several genes in the DNA
repair pathway are affected upon HDAC inhibition. HR DNA
repair is compromised upon HDAC inhibition, owing to both
downregulation of HR repair proteins, and impaired recruitment
of these proteins to the damaged site. Downregulation of the repair
genes is on account of a decrease in amount and promoter
recruitment of the E2F1 transcription factor. Since HDAC
inhibition affects several pathways that could potentially have an
impact on DNA repair, compromised DNA repair upon HDAC
inhibition could also be attributed to several other pathways
besides the ones investigated in this study. However, our study
does provide insights into the mechanism that governs downreg-
ulation of HR DNA repair genes upon HDAC inhibition which
can lead to rationale usage of HDACis in the clinics.
Materials and Methods
Cell culture and treatment
DU-145 and LNCAP PCA cell lines were obtained from ATCC
and maintained in RPMI-1640 (Invitrogen) media supplemented
with 10% fetal bovine serum. The cells were grown in a
humidified incubator at 37uC in a 5% CO2 atmosphere. A stock
solution of 1 M of sodium salt of VPA (Sigma, St. Louis,MO)
dissolved in complete RPMI media was used for all the
experiments. Cisplatin (Sigma, St. Louis,MO) and hydroxyurea
(Sigma, St. Louis,MO) were dissolved in water.
AFA Analysis
Microarray design and experimentation analysis may be
obtained from our recently published manuscript (Kortenhorst et
al., 2008). Functional Gene Sets were obtained from a number of
different genomic databases, encompassing distinct functional
themes, including Gene Ontology (GO) [47], the Kyoto
Encyclopedia of Genes and Genomes (KEGG) [48], the Molecular
Signatures Database [49], the UCSC Genome Browser database
[50], the Stanford Microarray Database (SMD) [51], and the
NCBI Entrez Gene database. Enrichment analysis was performed
using a one-sided Wilcoxon rank-sum test, separately for up- and
down-regulation, after ranking the genes by their signed or
absolute moderated t-statistics as previously described [52].
Multiple testing correction was performed to adjust the p-values
using the Benjamini and Hochberg method [53]. All such
computation analyses were performed using R/Bioconductor
functions and packages [54].
Real-time quantitative PCR (Q-PCR) analysis
Cells were lysed with Trizol (Invitrogen) and total RNA was
extracted. One microgram of total RNA was reverse transcribed
using Superscript reverse transcriptase (Invitrogen). One tenth of
the first strand cDNA reaction was used for Q-PCR amplification.
Q-PCR was performed in an iCYCLER real-time PCR machine
(Biorad) using SYBR-Green chemistry (BioRad). Test gene Ct
values were normalized to Ct values of the house keeper gene
HPRT and fold differences, as compared to untreated controls,
were calculated.
DNA Damaging Agents and Clonogenic Survival Assay
DU-145 cells were treated with varying concentrations of VPA
for 48 h; untreated cells were used as controls. After treatment,
cells were trypsinized and diluted to the appropriate cell density in
100-mm culture dishes to yield at least 50 colonies per dish
following irradiation. Dishes were then irradiated at 0.78 Gy/min
to the desired dose using a Gammacell 40 137Cs irradiator. Ten to
14 days after irradiation, colonies comprising at least 50 cells were
counted after staining with crystal violet. Cell survival was plotted
as a function of dose. Clonogenic assays for cisplatin and
hydroxyurea was performed by treating DU-145 cells with VPA
in combination with the above agents; untreated cells served as
controls. Forty eight hours after treatment, cells were trypsinized
and plated in 100-mm culture dishes to yield at least 50 colonies
per dish. Colonies were stained and visualized as above.
Comet Assay
Prostate cancer cells were treated with 1.5 mM VPA for 48 h
before being irradiated with 6 Gy of radiation to induce double
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strand breaks. At different intervals of repair cells were trypsinized
and subjected to an neutral comet assay using the Trevigen Comet
assay kit following the manufacturer’s protocol. Cells were imaged
using the Zeiss Axio Scope fluorescent microscope. Comet tails
were measured using the CometScore software and quantified. At
least a total of fifty cells were measured per timepoint.
Immunofluorescence and Repair Foci Recruitment
Studies
Cover slip cultures of DU145 and LNCaP cells were treated with
1.5 mM VPA for 48 h; untreated cells served as controls. After 48 h
cells were irradiated at 0.78 Gy/min to the desired dose using a
Gammacell 40 137Cs irradiator. The cells were allowed to repair for
4 h and then fixed and permeabilized with 3.7% paraformaldehyde
in PBS containing 0.125%Triton X-100 for 30 min. Fixed cells were
washed and blocked for 1 h in blocking buffer (1% BSA in PBS) and
probed with primary antibodies against phosphorylated H2AX
Ser139 (mouse monoclonal, Upstate Biotechnology), NBS1 (rabbit
polyclonal, Novus), Rad51 (mouse monoclonal, Abcam) and BRCA1
(mouse monoclonal, Ab-1, Calbiochem) at their respective dilutions
made in blocking buffer. The cells were washed with PBS and probed
with Alexa Fluor conjugated secondary antibodies (Molecular
Probes). The nuclei were counterstained with DAPI. H2AX foci
suggestive of DSBs was visualized under a fluorescent microscope and
one hundred cells were counted and graded depending on the
number of foci per cell. To investigate recruitment of repair proteins,
cells with .25 H2AX foci were included. BRCA1 and RAD51 foci
that colocalized with H2AX foci, suggestive of efficient recruitment,
were counted and grouped.
Immunoblotting
Cells were washed using 1X PBS and lysed on ice using RIPA
buffer containing 1X protease inhibitors (Roche) and 1X
PhosphoStop (Roche). 10–20 mg of protein was separated on a
4–15% SDS-PAGE gradient gel (Biorad). The separated proteins
were transferred onto a PVDF (Biorad) membrane. The
membrane was blocked in blocking buffer [100 mMTris-HCl
pH 7.4, 0.1% Tween20, 150 mM NaCl and 5%(w/v) nonfat milk]
for 1 h and incubated with primary antibodies in blocking buffer
at 1:4000 dilution, except for BRCA1 and Rad51 antibodies
which were used at 1:1000 dilution. The membrane was
developed with ECL chemiluminescence (Amersham Pharmacia)
after incubation with appropriate secondary antibody diluted to
1:5000 in the blocking buffer. Band intensity was normalized with
actin or vinculin as a loading control and quantified using
VersaDoc gel documenting system (Biorad).
TOPO IIa Activity Assay
Nuclear extract from VPA treated and control cells were
prepared for assaying TOPO IIa activity. Five microgram of
nuclear extract was used to assay TOPO IIa activity by the
Eukaryotic Topoisomerase IIa Assay Kit (Topogen).
HR Repair Assay
A plasmid based reporter assay was designed to score for HR
DNA repair efficiency after VPA treatment. The EGFP gene in
the pCMVEGFPN1 (Clontech) vector was mutated by a single
base pair insertion that changed the codon from GGA to TGA. A
promoter-less wild-type EGFP was PCR amplified using primers
that had a PciI site engineered in both the forward and reverse
primers, a BclI site was engineered ahead of the PciI site in the
reverse primer. The PCR fragment was purified and cloned in the
BspLU11I site of the pCMVEGFPN1mutant vector. A DBS was
introduced by digestion with BclI and the digested vector was
purified and transfected in control and VPA treated LNCaP cells,
24 h post-treatment. Twenty-four hour post-transfection green
cells that had efficient HR repair were scored by flow cytometry. A
control pCMVEGFPN1 (Clontech) vector, to monitor transfection
efficiency, was also included.
Promoter Reporter Assay
Proximal promoter regions of Rad51, Brca1, and Chk1 that
harbor E2F sites were amplified by PCR and cloned into the
pGL3 Basic luciferase reporter vector (Promega). DU-145 and
LNCaP cells were treated with varying concentrations of VPA for
24 h and the above reporter constructs were transfected along
with a renilla luciferase control vector in a 9:1 ratio respectively.
Twenty-four hours post transfection, cells were lysed and twenty
microliters were used to perform a luciferase assay using a dual
luciferase reporter assay kit (Promega). Light units were counted
using a luminometer and normalized to renilla luciferase activity.
Chromatin Immunoprecipitation (ChIP) Analysis
Forty-eight hours post-treatment with VPA, cells were treated with
formaldehyde (1% final concentration) and chromatin was cross-
linked for 15 min at 37uC. Crosslinking reactions were terminated by
the addition of 125 mMglycine for 5 min at room temperature. Cells
were washed with PBS, lysed, and chromatin was solubilized to
desired length by sonication. Immunoprecipitation of crosslinked
proteins was performed using acetylated H3 antibody (Upstate
Biotech), E2F1 (Millipore), E2F4 (Millipore), and E2F6 (Santacruz).
Isotype specific antibody processed soluble chromatin was main-
tained as a ChIP assay control. Immunoprecipitated DNA was
analyzed by PCR using Brca1, Rad51, Bubr1 and Chk1 promoter
specific primers flanking the E2F binding sites.
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